Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cpx-351
Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
P2
CCC
(51)
Crisantaspase
Acute Leukemia Of Ambiguous Lineage
National Cancer Institute (NCI)
P2
CCC
(51)
Crizotinib
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Crizotinib
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Dabrafenib
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Dasatinib
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Defactinib
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Defactinib
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Dexasone
Cholangiocarcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Dexasone
Colorectal Neoplasm
National Cancer Institute (NCI)
P2
CCC
(51)
Dexasone
Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
FAPI74
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
FAPI74
Gastric Cancer
National Cancer Institute (NCI)
P2
CCC
(51)
FAPI74
Hepatocellular Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
FAPI74
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
FAPI74
Sarcoma
National Cancer Institute (NCI)
P2
CCC
(51)
Fexagratinib
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Fexagratinib
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Fludeoxyglucose
Plasma Cell Leukemia
National Cancer Institute (NCI)
P2
CCC
(51)
Gsk-2636771
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Gsk-2636771
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
P2
CCC
(51)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Cervical Cancer
National Cancer Institute (NCI)
P2
CCC
(51)
Ipatasertib
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Ipatasertib
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Showing 2276 to 2300 of 3,272 assets
Previous
Page 92 of 131
Next